Possible Roles of IL-33 in the Innate-Adaptive Immune Crosstalk of Psoriasis Pathogenesis.
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
05
2019
accepted:
26
08
2019
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
6
5
2020
Statut:
epublish
Résumé
IL-33 belongs to the IL-1 family, playing a role in several biologic processes as well as in the pathogenesis of different diseases, including skin pathologies. It acts as an alarmin, released by damaged cells. Binding to a ST2 receptor, it stimulates many immune cells such as ILC2 and Th2 cells. IL-33/ST2 axis seems to be involved in Th17 response. According to this, a review was performed to analyze if IL-33 even interplay in the onset of psoriasis, a Th1/Th17 inflammatory disease. Data obtained from the included articles are study author name, publication date, group studied, clinical and biological variables, laboratory tests, and outcome of interest of the study. Data are obtained from the 19 studies identified, which assessed the association between IL-33 and psoriasis. It seems to promote the innate-adaptive immune crosstalk: it could induce mast cells and neutrophil response after being released by injured keratinocytes and after stimulation by some cytokines, in particular TNF The core of the future research on psoriasis could be to fully understand the role of this complex cytokine, in order also to find a new therapeutic approach.
Sections du résumé
BACKGROUND
BACKGROUND
IL-33 belongs to the IL-1 family, playing a role in several biologic processes as well as in the pathogenesis of different diseases, including skin pathologies. It acts as an alarmin, released by damaged cells. Binding to a ST2 receptor, it stimulates many immune cells such as ILC2 and Th2 cells. IL-33/ST2 axis seems to be involved in Th17 response. According to this, a review was performed to analyze if IL-33 even interplay in the onset of psoriasis, a Th1/Th17 inflammatory disease.
METHODS
METHODS
Data obtained from the included articles are study author name, publication date, group studied, clinical and biological variables, laboratory tests, and outcome of interest of the study.
RESULTS
RESULTS
Data are obtained from the 19 studies identified, which assessed the association between IL-33 and psoriasis.
DISCUSSION
CONCLUSIONS
It seems to promote the innate-adaptive immune crosstalk: it could induce mast cells and neutrophil response after being released by injured keratinocytes and after stimulation by some cytokines, in particular TNF
CONCLUSION
CONCLUSIONS
The core of the future research on psoriasis could be to fully understand the role of this complex cytokine, in order also to find a new therapeutic approach.
Identifiants
pubmed: 31736655
doi: 10.1155/2019/7158014
pmc: PMC6815589
doi:
Substances chimiques
Interleukin-33
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7158014Informations de copyright
Copyright © 2019 Serafinella Patrizia Cannavò et al.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
J Dermatol Sci. 2013 Aug;71(2):107-14
pubmed: 23764374
Arch Dermatol Res. 2016 Sep;308(7):527-30
pubmed: 27388717
Nat Immunol. 2016 Feb;17(2):122-31
pubmed: 26784265
Arch Dermatol Res. 2008 Oct;300(9):461-78
pubmed: 18719932
J Invest Dermatol. 2012 Nov;132(11):2593-600
pubmed: 22673732
Curr Opin Immunol. 2014 Dec;31:31-7
pubmed: 25278425
J Immunol. 2007 Aug 15;179(4):2051-4
pubmed: 17675461
J Dermatol Sci. 2012 Jan;65(1):72-4
pubmed: 22100205
Lab Invest. 2007 Oct;87(10):971-8
pubmed: 17700564
Joint Bone Spine. 2012 Jan;79(1):32-7
pubmed: 21441054
PLoS One. 2013;8(2):e52144
pubmed: 23468834
Expert Opin Ther Targets. 2017 Dec;21(12):1141-1152
pubmed: 29076792
Angiology. 2018 Jan;69(1):31-37
pubmed: 29212353
Arthritis Res Ther. 2016 Jun 18;18(1):143
pubmed: 27317338
J Allergy Clin Immunol. 2017 Dec;140(6):1622-1631
pubmed: 29038009
Front Immunol. 2017 Apr 24;8:475
pubmed: 28484466
Acta Derm Venereol. 2015 May;95(5):536-41
pubmed: 25425229
Allergy Asthma Proc. 2017 Jan 1;38(1):9-15
pubmed: 28052797
Dermatology. 2017 May 10;233(1):37-46
pubmed: 28490011
Arch Dermatol Res. 2016 Jul;308(5):287-96
pubmed: 26969580
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
J Pharmacol Exp Ther. 2015 Jul;354(1):24-31
pubmed: 25906776
Immunobiology. 2015 Aug;220(8):954-63
pubmed: 25747940
J Invest Dermatol. 2018 Mar;138(3):570-579
pubmed: 29045819
Clin Rev Allergy Immunol. 2016 Jun;50(3):377-89
pubmed: 27025861
Sci Rep. 2016 Aug 24;6:32116
pubmed: 27554830
Rheum Dis Clin North Am. 2015 Nov;41(4):643-63
pubmed: 26476224
Immunol Lett. 2015 Mar;164(1):11-7
pubmed: 25662624
Exp Dermatol. 2012 Nov;21(11):892-4
pubmed: 23163661
Eur J Immunol. 2011 Aug;41(8):2229-37
pubmed: 21674479
PLoS One. 2016 Aug 22;11(8):e0161507
pubmed: 27548066
Mediators Inflamm. 2018 Mar 11;2018:3858032
pubmed: 29713240
Iran J Allergy Asthma Immunol. 2018 Apr;17(2):179-187
pubmed: 29757591
Clin Exp Immunol. 2012 Sep;169(3):311-9
pubmed: 22861371
Acta Derm Venereol. 2015 Apr;95(4):432-8
pubmed: 25178645
J Immunol. 2016 Nov 1;197(9):3662-3668
pubmed: 27694493
Exp Ther Med. 2015 Oct;10(4):1573-1577
pubmed: 26622528
J Bone Miner Res. 2011 Apr;26(4):704-17
pubmed: 20939024
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
Clin Exp Dermatol. 2016 Mar;41(2):183-9
pubmed: 25976154
J Cutan Med Surg. 2019 Mar/Apr;23(2):204-221
pubmed: 30463416
J Dermatol. 2018 Mar;45(3):322-325
pubmed: 28836690
Eur J Immunol. 2019 Sep;49(9):1306-1320
pubmed: 31250428
Nat Rev Immunol. 2016 Nov;16(11):676-689
pubmed: 27640624
Nat Immunol. 2013 Dec;14(12):1229-36
pubmed: 24141388
Int Immunopharmacol. 2019 Aug;73:442-450
pubmed: 31154289
J Invest Dermatol. 2015 Jul;135(7):1771-1780
pubmed: 25739051
Nat Immunol. 2018 Oct;19(10):1042-1044
pubmed: 30201993
J Invest Dermatol. 2016 Feb;136(2):365-371
pubmed: 26802234
Eur J Immunol. 2017 Jun;47(6):1062-1074
pubmed: 28386999
Arch Dermatol Res. 2014 Apr;306(3):299-304
pubmed: 24522896
Cell Mol Immunol. 2017 Jan;14(1):43-64
pubmed: 27569562
Am J Pathol. 2011 Jul;179(1):211-22
pubmed: 21703403
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2646-2651
pubmed: 30696763
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4448-53
pubmed: 20160089
J Autoimmun. 2010 May;34(3):J314-21
pubmed: 20034760
Lancet. 2018 Jun 2;391(10136):2273-2284
pubmed: 29893226
Cell Biol Int. 2014 May;38(5):655-62
pubmed: 24448827
Trends Immunol. 2016 May;37(5):321-333
pubmed: 27055914
Nature. 2014 Sep 25;513(7519):564-568
pubmed: 25043027
Clin Dermatol. 2014 May-Jun;32(3):343-50
pubmed: 24767182